29 July 2019 in Scientific Reports
Guar gum is an important raw material in the food, textile and oil industries, but the biosynthesis of guar gum remains unclear. To illuminate the genes involved in guar gum biosynthesis, guar beans from 30 and 40 days after flowering (DAF) were used for RNA sequencing in this study. A total of 2,535 and 2,724 preferentially expressed genes were found in 30 and 40 DAF endosperm, and 3,720 and 2,530 preferentially expressed genes were found in 30 and 40 DAF embryos, respectively. Of these, mannan synthase genes, α-galactosyltransferase genes and cellulose synthase genes were preferentially expressed in the endosperm from 30 and 40 DAF. The high expression level of these glycometabolism genes in endosperm is consistent with the expectation that the main component of guar gum is galactomannan. We believe that genes related to guar gum biosynthesis found in this study will be useful for both new variety development via genetic engineering and synthetic biology research on guar gum biosynthesis in the future.
13 May 2023 in Journal of Magnetic Resonance Imaging
3 April 2026 in Interdisciplinary Medicine
The brain‐gut axis shapes Crohn's disease (CD) pathogenesis, yet CD‐associated neurophenotypes lack defined clinical and mechanistic significance. This work aimed to define these neurophenotypes, assess their prognostic impact, elucidate neurophenotype‐driven progression mechanisms using multi‐omics, and validate their therapeutic potential in vivo. 109 CD patients were prospectively recruited from two centers and underwent baseline multimodal neuro‐MRI, MR enterography, ileocolonoscopy, and fecal/blood sample collection. The neurophenotypes were characterized using a multimodal neuro‐MRI model developed from 13 of 13,870 features. 83 patients were followed up for disease progression, with repeated brain‐gut assessments. Multi‐omics (fecal microbiome/metabolomics, serum metabolomics/neurotransmitters) were used to decode the mechanisms underlying neurophenotype‐driven progression. Dextran sulfate sodium (DSS)‐induced colitis mice with different neurophenotypes were treated with repeated transcranial magnetic stimulation (rTMS) to explore its therapeutic potential. Multimodal neuro‐MRI accurately mapped CD‐specific neural signatures, stratifying patients into high‐risk (neurophenotype score ≥ 0.45) and low‐risk neurophenotypes with robust cross‐center validity (training cohort AUC = 0.842, test cohort AUC = 0.824). High‐risk neurophenotype was identified as an independent predictor of accelerated disease progression (Hazard ratio = 15.46, p = 0.030), independent of intestinal inflammation. Integrated multi‐omics revealed that the high‐risk neurophenotype contributed to CD progression through microbial‐metabolic‐neurotransmitter networks where tryptophan emerged as the central regulatory hub. Serum tryptophan levels were negatively correlated with neurophenotype severity and intestinal disease progression. rTMS targeting high‐risk neurophenotype in DSS‐induced colitis mice elevated tryptophan levels and ameliorated intestinal disease activity. This study redefines the high‐risk neurophenotype as a sustained pathogenic driver rather than a mere phenomenon, proposing brain‐gut axis modulation as a promising therapeutic strategy distinct from conventional anti‐inflammatory approaches.